gemcitabine + placebo

Gemcitabine + placebo refers to a combination regimen used in clinical trials where patients receive gemcitabine, a nucleoside analog and antimetabolite chemotherapeutic agent, together with an inert substance (placebo) that has no therapeutic effect. This combination is typically used as a control arm in randomized controlled trials to assess the efficacy and safety of new investigational drugs or regimens when added to standard gemcitabine therapy. Gemcitabine works by being incorporated into DNA during replication, leading to masked chain termination and apoptosis of rapidly dividing cancer cells. The placebo serves as a comparator to ensure unbiased evaluation of the experimental intervention's effects[1][9].

Brand names

GemzarInfugem

Other names

Gemcitabine plus placebo